Loading company details...
Latest Form 4 (Nov 13, 2026): Gilmore Neil O'Neill (CEO): Sale of 21,164 shares, $51.1K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Nov 13, 2026 | Gilmore Neil O'Neill, CEO | Sale | 21,164 | $51.1K |
| Nov 13, 2026 | Linda Burkly, EVP, CHIEF SCIENTIFIC OFFICER | Sale | 7,814 | $18.9K |
| Nov 6, 2026 | Linda Burkly, EVP, CHIEF SCIENTIFIC OFFICER | Grant/Award | 16,533 | n/a |
| Nov 6, 2026 | Gilmore Neil O'Neill, CEO | Grant/Award | 43,567 | n/a |
| Sep 9, 2026 | Daniel Scott Ory, EVP, Chief Medical Officer | Grant/Award | 950,000 | n/a |
| Sep 4, 2026 | Linda Burkly, EVP, CHIEF SCIENTIFIC OFFICER | Sale | 709 | $2.2K |
| Sep 4, 2026 | Amy Parison, SVP, Chief Financial Officer | Sale | 453 | $1.4K |
| Sep 4, 2026 | Gilmore Neil O'Neill, CEO | Sale | 5,124 | $15.6K |
| Aug 7, 2026 | Patrick Thomas Ellinor II | Grant/Award | 103,400 | n/a |
| Aug 5, 2026 | Amy Parison, SVP, Chief Financial Officer | Sale | 678 | $1.7K |